CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 10 enrolled
Drug / intervention
Allopregnanolone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04015869
NCT04015869Phase 1Completed
CompareCT.gov

Effect of Allopregnanolone on Stress-induced Craving

Yale University·interventional·Posted Jul 11, 2019·Updated Aug 22, 2025

In Brief

A Phase 1 clinical trial evaluating Allopregnanolone and Placebos for Alcohol Use Disorder. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The goal of this study is to determine whether intravenous infusion of allopregnanolone (ALLO) attenuates stress-induced craving and stress-induced anxiety in a clinical laboratory setting. The secondary objective of this project is to characterize the behavioral effects of ALLO in heavy drinkers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Use Disorder
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedJul 11, 2019
Enrollment StartJul 1, 2019
Primary CompletionSep 1, 2023
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 7.0 years ago

Interventions

Allopregnanolonedrug

neurosteroid

Placebosdrug

placebo